SHR3680 plus ADT improved radiographic progression-free survival and overall survival, when compared with bicalutamide plus ADT.
Among patients receiving radiation therapy (RT) for prostate cancer, intensity-modulated radiation therapy is significantly associated with a reduced risk for second primary solid malignancies compared with 3D conformal RT.
Updated findings from the ENZAMET trial show that adding enzalutamide to testosterone suppression offers clinically meaningful improvements in overall survival.
In a study, aviremic recipients of HCV-positive and HCV-negative deceased donor kidneys had similar 12-month transplant outcomes.
Treatment with lutetium-177 PSMA offers overall survival similar to cabazitaxel, with lower adverse event rates and better patient-reported quality-of-life.
The increased death risk associated with type 2 diabetes in kidney transplant recipients does not vary significantly by body mass index, according to investigators.
Investigators observed a complete response in more than half of patients treated with tislelizumab plus nab-paclitaxel for high-risk NMIBC that was not completely resectable.
Study findings “have implications for development of SOT-specific approaches for risk stratification that may be applied to patient evaluation and triage,” according to investigators.
Everolimus improved recurrence-free survival in patients with very high-risk disease but not in those with intermediate high-risk disease.